Avanços na detecção e tratamento do câncer ginecológico: novas triagens e tratamentos emergentes
Resumo
O câncer é a segunda principal causa de morte global, causando cerca de 9,6 milhões de óbitos anuais, com aumento da incidência devido à maior expectativa de vida e exposição a fatores de risco. Entre os cânceres femininos, o cervical é o mais comum e tem uma carga desproporcional em países em desenvolvimento, com alta incidência e mortalidade. O tratamento para cânceres ginecológicos inclui quimioterapia e terapias direcionadas, com avanços recentes na medicina personalizada. Portanto, este artigo visa explorar os avanços na detecção e tratamento do câncer ginecológico, destacando: os progressos nas técnicas de triagem e novos biomarcadores; as estratégias de prevenção; e as novas terapias emergentes, incluindo terapias direcionadas e imunoterapia. Trata-se de uma revisão da literatura utilizando artigos de bases de dados renomadas, como PubMed e Scopus, publicados nos últimos 10 anos. A análise crítica dos estudos selecionados considera a qualidade metodológica e a eficácia das abordagens inovadoras. Os avanços na detecção precoce e no tratamento do câncer ginecológico têm melhorado significativamente os cuidados com as pacientes, com a triagem eficaz e a vacinação contra o HPV reduzindo a incidência de câncer cervical. A detecção precoce de câncer ovariano ainda é desafiadora, mas novas estratégias e biomarcadores oferecem esperança. Tratamentos emergentes como inibidores PARP e imunoterapia estão oferecendo novas perspectivas para casos avançados. Futuras pesquisas devem focar em melhorar a triagem e a eficácia das novas terapias para otimizar o manejo da doença.
Referências
ABDALLA, S. et al. Multiparametric transvaginal ultrasound in the diagnosis of endometrial cancer in post-menopausal bleeding: diagnostic performance of a transvaginal algorithm and reproducibility amongst less experienced observers. The British Journal of Radiology, v. 94, n. 1119, p. 20201195, 2021.
AKTER, S. et al. Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements. Cells, v. 11, n. 4, p. 650, 2022.
ALI, F.; KUELKER, R; WASSIE, B. Understanding cervical cancer in the context of developing countries. Annals of Tropical Medicine & Public Health, v. 5, n. 1, 2012.
BALAKRISHNAN, B. R. et al. Cervical cancer prevention and treatment: An overview. Research Journal of Pharmacy and Technology, v. 14, n. 4, p. 2353-2359, 2021.
BERGMAN, H. et al. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related disease in females and males. Cochrane database of systematic reviews, v. 2019, n. 11, 2019.
BOGANI, G. et al. HPV-related lesions after hysterectomy for high-grade cervical intraepithelial neoplasia and early-stage cervical cancer: a focus on the potential role of vaccination. Tumori Journal, v. 110, n. 2, p. 139-145, 2024.
BONTE, A. et al. Quality indicators for the management of endometrial, cervical and ovarian cancer. European Journal of Surgical Oncology, v. 45, n. 4, p. 528-537, 2019.
BRUYN, C. et al. Neo-adjuvant chemotherapy reduces, and surgery increases immunosuppression in first-line treatment for ovarian cancer. Cancers, v. 13, n. 23, p. 5899, 2021.
CAMMARATA, G. et al. Extracellular vesicles-ceRNAs as ovarian cancer biomarkers: looking into circRNA-miRNA-mRNA code. Cancers, v. 14, n. 14, p. 3404, 2022.
CARDOSO, M. et al. Putative biomarkers for cervical cancer: SNVs, methylation and expression profiles. Mutation Research/Reviews in Mutation Research, v. 773, p. 161-173, 2017.
CASANOVA, J. et al. Prognosis of polymerase epsilon (POLE) mutation in high-grade endometrioid endometrial cancer: Systematic review and meta-analysis. Gynecologic Oncology, v. 182, p. 99-107, 2024.
CHUNG, Y. S. et al. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer. American Journal of Obstetrics and Gynecology, v. 224, n. 4, p. 370. e1-370. e13, 2021.
CLARKE, M. A. et al. Association of endometrial cancer risk with postmenopausal bleeding in women: a systematic review and meta-analysis. JAMA internal medicine, v. 178, n. 9, p. 1210-1222, 2018.
COLOMBO, N. et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. New England Journal of Medicine, v. 385, n. 20, p. 1856-1867, 2021. MCNAMARA, Blair et al. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. Expert Opinion on Biological Therapy, v. 23, n. 3, p. 227-233, 2023.
CROSBY, D. et al. Early detection of cancer. Science, v. 375, n. 6586, p. eaay9040, 2022.
D'AUGÈ, T. G. et al. Prevention, screening, treatment and follow-up of gynecological cancers: state of art and future perspectives. Clinical and Experimental Obstetrics & Gynecology, v. 50, n. 8, p. 160, 2023.
DESAI, K. T. et al. The development of “automated visual evaluation” for cervical cancer screening: the promise and challenges in adapting deep‐learning for clinical testing. International journal of cancer, v. 150, n. 5, p. 741-752, 2022.
FABBRO, M. et al. Conditional probability of survival and prognostic factors in long-term survivors of high-grade serous ovarian cancer. Cancers, v. 12, n. 8, p. 2184, 2020.
FDA News Release. FDA grants accelerated approval to new treatment for advanced ovarian cancer. Disponível em: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm533873.htm. Acesso em: 7 ago. 2024.
FU, L. et al. Deep learning based cervical screening by the cross-modal integration of colposcopy, cytology, and HPV test. International Journal of Medical Informatics, v. 159, p. 104675, 2022.
GOPU, P. et al. Updates on systemic therapy for cervical cancer. Indian Journal of Medical Research, v. 154, n. 2, p. 293-302, 2021.
IKEDA, S. et al. Human papillomavirus vaccine to prevent cervical intraepithelial neoplasia in Japan: a nationwide case‐control study. Cancer science, v. 112, n. 2, p. 839-846, 2021.
KARIM, Z. et al. Cervical Cancer Screening Using Pap Smear Test and Clinical Correlation. Awareness to Control Dengue Fever, v. 32, n. 12, p. 143, 2021.
KIM, K. et al. Clinicopathologic and protein markers distinguishing the “polymerase epsilon exonuclease” from the “copy number low” subtype of endometrial cancer. Journal of Gynecologic Oncology, v. 33, n. 3, 2022.
LEI, J. et al. HPV vaccination and the risk of invasive cervical cancer. New England Journal of Medicine, v. 383, n. 14, p. 1340-1348, 2020.
MACEDO, J. et al. Genomic profiling reveals the pivotal role of hrHPV driving copy number and gene expression alterations, including mRNA downregulation of TP53 and RB1 in penile cancer. Molecular Carcinogenesis, v. 59, n. 6, p. 604-617, 2020.
MANCHANDA, R. Special issue “gynaecological cancers risk: breast cancer, ovarian cancer and endometrial cancer”. Cancers, v. 14, n. 2, p. 319, 2022.
MORGAN, R. J. et al. Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, v. 14, n. 9, p. 1134-1163, 2016.
NASH, Z; MENON, U. Ovarian cancer screening: Current status and future directions. Best practice & research Clinical obstetrics & gynaecology, v. 65, p. 32-45, 2020.
ORONSKY, B. et al. A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer. Medical oncology, v. 34, p. 1-7, 2017.
RATNER, E. S. et al. Sexuality and intimacy after gynecological cancer. Maturitas, v. 66, n. 1, p. 23-26, 2010.
REES, C. P.; BRHLIKOVA, P.; POLLOCK, A. M. Will HPV vaccination prevent cervical cancer?. Journal of the Royal Society of Medicine, v. 113, n. 2, p. 64-78, 2020.
RINGLEY, J. T. et al. Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer: A drug class review. Pharmacy and Therapeutics, v. 43, n. 9, p. 549, 2018.
SALVO, G. et al. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: a review of gaps and questions that remain. International Journal of Gynecologic Cancer, v. 30, n. 6, 2020.
SELMOUNI, F. et al. Effectiveness of Artificial Intelligence–Assisted Decision-making to Improve Vulnerable Women’s Participation in Cervical Cancer Screening in France: Protocol for a Cluster Randomized Controlled Trial (AppDate-You). JMIR research protocols, v. 11, n. 8, p. e39288, 2022.
SHASTRI, S. S. et al. Secondary prevention of cervical cancer: ASCO resource–stratified guideline update. JCO Global Oncology, v. 8, p. e2200217, 2022.
SONE, K. et al. Application of artificial intelligence in gynecologic malignancies: A review. Journal of Obstetrics and Gynaecology Research, v. 47, n. 8, p. 2577-2585, 2021.
SPAGNOL, G. et al. 3D transvaginal ultrasound vs magnetic resonance imaging for preoperative staging of myometrial and cervical invasion in patients with endometrial cancer: systematic review and meta-analysis. Ultrasound Obstet. Gynecol, v. 10, 2022.
USHIJIMA, K. Treatment for recurrent ovarian cancer—at first relapse. Journal of oncology, v. 2010, n. 1, p. 497429, 2010.
WANG, Q. et al. Targeted therapies in gynecological cancers: A comprehensive review of clinical evidence. Signal Transduction and Targeted Therapy, v. 5, n. 1, p. 137, 2020.
WANG, R. et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer letters, v. 471, p. 88-102, 2020.
WANG, Z. et al. Trends and age-period-cohort effects on mortality of the three major gynecologic cancers in China from 1990 to 2019: Cervical, ovarian and uterine cancer. Gynecologic oncology, v. 163, n. 2, p. 358-363, 2021.
WHO. World Health Organization, CANCER TODAY. 2023b. Disponível em: https://gco.iarc.fr/today/online-analysispie?v=2020&mode=cancer&mode_population=continents&population=900&populations=900&key=total&sex=2&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=15&grou. Acesso em: 6 ago. 2024.
WHO. WORLD HEALTH ORGANIZATION. World malaria report 2023. World Health Organization, 2023a.
YANG, C. et al. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Frontiers in immunology, v. 11, p. 577869, 2020.
ZHENG, F. et al. Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. Biomedicine & Pharmacotherapy, v. 123, p. 109661, 2020.
Downloads
Publicado
Versões
- 2024-09-01 (2)
- 2024-08-10 (1)
Como Citar
Licença
Copyright (c) 2024 Kaio Weslley Ramalho Lacerda, Antonio Wilson Junior Ramalho Lacerda, Wendel Sebastian Ramalho Lacerda, Patricia Peixoto Custódio, Italo Rossi Roseno Martins
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Creative Commons 
.png){kind=logo}
